Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Pharmaceutical Segment — SG&A Expense by Year
Pharmaceutical Segment — SG&A Expense ($M) ($M)
Merck Pharmaceutical Segment — SG&A Expense: $5,874M in FY2025, down 4.1% from a year earlier.
Latest, FY2025
5,874
Period ended Dec 31, 2025
Change on a year earlier
-4.1%
6,128 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Segment Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pharmaceutical Segment — SG&A Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,874 | -4.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 6,128 | +3.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 5,903 | +7.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 5,474 | – | Form 10-K (filed 2025-02-25) ↗ |
Cite this data
StockData. (2026). Merck Pharmaceutical Segment — SG&A Expense ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db-seg-pharma-sga
See every metric in the Merck KPI table. Data updated Oct 26, 2026.